Syneron Medical Ltd. to Present the New GentleMax Pro(R) at the 2012 South Beach Symposium

WAYLAND, MA--(Marketwire - February 14, 2012) - Syneron Medical Ltd. (NASDAQ: ELOS), www.syneron.com, the global leader in medical aesthetic products and technology, will launch the much anticipated GentleMax Pro® at the 2012 South Beach Symposium at the Lowes Miami Beach Hotel in Miami, Florida on February 16 - 20, 2012. GentleMax Pro® is a solid state, dual wavelength laser platform that offers the maximum performance in speed and reliability for the largest energy-based, nonsurgical cosmetic procedure -- laser hair removal.

“Building upon the solid reputation and Gold Standard technology of the Gentle Family of lasers, the challenge we set for GentleMax Pro was simple -- to design the next generation device that will outperform the current Gold Standard in high-speed laser hair removal,” said Louis P. Scafuri, Chief Executive Officer of Syneron Medical and Candela Corporation. “Not only is the GentleMax Pro smaller, lighter and faster but we’ve added over a dozen new features and refined existing features to the finest detail starting with the way it sounds all the way up to how fast it works -- making it a more thorough and truly enhanced experience for our customers and their patients.”

Redesigned from the ground up, the GentleMax Pro delivers robust performance with high reliability for the busy professional hair removal and aesthetic treatment environments. “When it comes to offering fast and effective laser hair removal every specification matters,” said Ellen H. Frankel, M.D., dermatologist and Medical Director at Rejuvaderm Medi Spa in Cranston, Rhode Island. “The dual wavelength of the GentleMax Pro allows us to treat a wider range of patients with one device and having the industry’s largest spot size of 18mm with tremendous fluence option and pulse width range puts a whole new meaning behind high-speed laser hair removal.”

In addition to many of the system refinements, the GentleMax Pro also comes equipped with the multi-spot Specialty Delivery System, providing the option to treat facial veins, leg veins and other vascular lesions including hemangioma and port wine stains with 1.5, 3.0 and 3x10 mm treatment spots. “At the Gold Laser Academy (www.goldlaseracademy.com) we make certain to provide our attendees with in-depth, hands-on, training utilizing all the Gold Standard and cutting edge technologies in aesthetics,” said Alan Gold, M.D., plastic surgeon and Director of the Gold Laser Academy in Syosset, New York. “The GentleMax Pro has been a great addition to our armamentarium -- all of the users from trainers to attendees have been very impressed with the performance and versatility of the device.”

Attendees at the 2012 South Beach Symposium will be first to see the new Gold-Standard in laser hair removal. Demonstration of the new GentleMax Pro will occur throughout the symposium including expert physician advice by Daniel Wasserman, M.D., board certified Dermatologist in Napels, Florida, on Saturday, February 18, 2012 from 4pm - 4:20pm ET at the Syneron-Candela booth.

For more information about Syneron-Candela’s broad product offering, visit www.syneron.com.

About Syneron Medical Ltd.
Syneron Medical Ltd. -- a company devoted to real technology, real science and real results -- is the leading global aesthetic device company with a comprehensive product portfolio and a global distribution footprint. The Company’s technology enables physicians to provide advanced solutions for a broad range of medical-aesthetic applications including body contouring, hair removal, wrinkle reduction, rejuvenation of the skin’s appearance through the treatment of superficial benign vascular and pigmented lesions, and the treatment of acne, leg veins and cellulite. The Company sells its products under two distinct brands, Syneron and Candela. The Company’s aspiration and commitment to innovation expands Syneron’s offering beyond medical device into the largest in-demand applications in beauty -- skin lightening. Founded in 2000, the corporate, R&D, and manufacturing headquarters for Syneron Medical Ltd. are located in Israel. Syneron also has R&D and manufacturing operations in the US. The company markets and services and supports its products in 86 countries. It has offices in North America, France, Germany, Italy, Portugal, Spain, UK, Australia, China, Japan, and Hong Kong and distributors worldwide. Additional information can be found at www.syneron.com.

SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS
Any statements contained in this document regarding future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Further, any statements that are not statements of historical fact (including statements containing “believes,” “anticipates,” “plans,” “expects,” “may,” “will,” “would,” “intends,” “estimates” and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including the risk that the businesses of Syneron and Candela may not be integrated successfully; the risk that the merger transaction with Candela may involve unexpected costs or unexpected liabilities; the risk that synergies from the merger transaction may not be fully realized or may take longer to realize than expected; the risk that disruptions from the merger transaction make it more difficult to maintain relationships with customers, employees, or suppliers; as well as the risks set forth in Syneron Medical Ltd.'s most recent Annual Report on Form 20-F, and the other factors described in the filings that Syneron Medical Ltd. makes with the SEC from time to time. If one or more of these factors materialize, or if any underlying assumptions prove incorrect, Syneron Medical Ltd.'s actual results, performance or achievements may vary materially from any future results, performance or achievements expressed or implied by these forward-looking statements.

In addition, the statements in this document reflect the expectations and beliefs of Syneron Medical Ltd. as of the date of this document. Syneron Medical Ltd. anticipates that subsequent events and developments will cause its expectations and beliefs to change. However, while Syneron Medical Ltd. may elect to update these forward-looking statements publicly in the future, it specifically disclaims any obligation to do so. The forward-looking statements of Syneron Medical Ltd. do not reflect the potential impact of any future dispositions or strategic transactions that may be undertaken. These forward-looking statements should not be relied upon as representing Syneron Medical Ltd.'s views as of any date after the date of this document.